The Time To Buy Editas Medicine Inc (NASDAQ: EDIT) Is Now

During the last session, Editas Medicine Inc (NASDAQ:EDIT)’s traded shares were 1.81 million, with the beta value of the company hitting 2.02. At the end of the trading day, the stock’s price was $6.86, reflecting an intraday loss of -0.15% or -$0.01. The 52-week high for the EDIT share is $11.91, that puts it down -73.62 from that peak though still a striking 11.37% gain since the share price plummeted to a 52-week low of $6.08. The company’s market capitalization is $561.22M, and the average intraday trading volume over the past 10 days was 1.68 million shares, and the average trade volume was 1.85 million shares over the past three months.

Editas Medicine Inc (NASDAQ:EDIT) trade information

Editas Medicine Inc (EDIT) registered a -0.15% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.15% in intraday trading to $6.86, hitting a weekly high. The stock’s 5-day price performance is -4.99%, and it has moved by -30.85% in 30 days. Based on these gigs, the overall price performance for the year is -5.38%. The short interest in Editas Medicine Inc (NASDAQ:EDIT) is 13.93 million shares and it means that shorts have 5.91 day(s) to cover.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Editas Medicine Inc (EDIT) estimates and forecasts

Statistics show that Editas Medicine Inc has underperformed its competitors in share price, compared to the industry in which it operates. Editas Medicine Inc (EDIT) shares have gone down -3.92% during the last six months, with a year-to-date growth rate less than the industry average at -29.21% against 13.60. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 7.00% this quarter and then drop -19.60% in the quarter after that. In the rating firms’ projections, revenue will decrease -53.40% compared to the previous financial year.

Revenue for the current quarter is expected to be $8.2 million as predicted by 13 analyst(s). Meanwhile, a consensus of 13 analyst(s) estimates revenue growth to $6.44 million by the end of Jun 2024. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $9.85 million and $4.17 million respectively. In this case, analysts expect current quarter sales to shrink by -16.80% and then jump by 54.40% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 2.88%. While earnings are projected to return -27.84% in 2024, the next five years will return 1.70% per annum.

EDIT Dividends

Editas Medicine Inc is due to release its next quarterly earnings between May 03 and May 07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Editas Medicine Inc (NASDAQ:EDIT)’s Major holders

Editas Medicine Inc insiders own 0.91% of total outstanding shares while institutional holders control 75.61%, with the float percentage being 76.30%. Vanguard Group Inc is the largest shareholder of the company, while 310 institutions own stock in it. As of Jun 29, 2023, the company held over 8.17 million shares (or 10.00% of all shares), a total value of $67.2 million in shares.

The next largest institutional holding, with 7.6 million shares, is of Blackrock Inc.’s that is approximately 9.30% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $62.51 million.

Also, the Mutual Funds coming in first place with the largest holdings of Editas Medicine Inc (EDIT) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. Data provided on Aug 30, 2023 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 4.85 million shares. This amounts to just over 5.94 percent of the company’s overall shares, with a $43.18 million market value. The same data shows that the other fund manager holds slightly less at 2.49 million, or about 3.05% of the stock, which is worth about $20.51 million.